the aid library

LIST OPTIONS

Filter

6162

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows: National action plan key activities, prioritized for the current context and the current ... more

Responding to communicable and noncommunicable diseases: progress report 2020-2022

World Health Organization WHO (2023) C_WHO

Significant progress has been made in the eradication of three priority diseases in the African Region, as a result of extensive collaboration between the Regional Office, WHO country offices and countries. For example, in August 2020, the region was certified free of wild poliovirus. In the area of... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Type 2 diabetes in adults

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2023) CC2

The document provides the NICE Quality Standard for managing Type 2 diabetes in adults (QS209). It outlines evidence-based recommendations for preventing Type 2 diabetes, structured education, continuous glucose monitoring (CGM), medication such as SGLT2 inhibitors, and regular care processes to mon... more

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Global status report on noncommunicable diseases 2014 WHO

World Health Organization (WHO) World Health Organization (WHO) (2014) C_WHO

This global status report on prevention and control of NCDs (2014), is framed around the nine voluntary global targets. The report provides data on the current situation, identifying bottlenecks as well as opportunities and priority actions for attaining the targets. The 2010 baseline estimates on N... more

Toolkit for developing a multisectoral action plan for noncommunicable diseases: module 1: conducting a comprehensive assessment

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

One of the first steps in developing a multisectoral action plan (MSAP) is to use a situation analysis to provide a comprehensive assessment of the health needs, prevailing risks and the context of the area to which the plan will apply. This will help countries, regions, provinces or cities intendi... more

Advancing the global agenda on prevention and control of noncommunicable diseases 2000 to 2020

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

This document highlights landmarks and key milestones in the development and implementation of the global agenda for noncommunicable diseases (NCDs) over the last two decades. It summarizes where the world was in 2000, where it is in 2022, and where the world wants to be in terms of NCD prevention a... more

Global Strategy for Asthma Management and Prevention (2019 update)

Global Initiative for Asthma (2019) CC2

The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessi... more

Addressing gender inequalities in national action plans on antimicrobial resistance

World Health Organisation (WHO) (2024) C_WHO

National action plans on antimicrobial resistance (AMR) often overlook the critical intersection of gender, despite evidence that exposure and susceptibility to infection, health-seeking behaviours, as well as antimicrobial prescribing and use patterns are all influenced by gender.

Sexual, reproductive, maternal, newborn, child and adolescent health: report on the 2023 policy survey

World Health Organisation (WHO) (2024) C_WHO

Evidence- and rights-based national policies, guidelines and legislation play a key role in improving sexual, reproductive, maternal, newborn, child and adolescent health (SRMNCAH), framing the enabling environment for equitable provision and accessibility of quality services. The SRMNCAH policy sur... more

SEAHEARTS Monitoring Framework

World Health Organisation (WHO) (2024) C_WHO

Monitoring Framework

Download (7)

View PDF (2)

Helping Elderly 33

Tolkien Jessica ProQuest Dissertations & Theses (2025) CC

Some testing done

Mauritius National Action Plan on Antimicrobial Resistance 2017-2021

Ministry of Health and Quality of Life Mauritius (2017) C2

Antimicrobial resistance has become a serious public health threat for effective treatment of an ever increasing range of infections caused by bacteria, parasites, viruses and fungi. When infections can no longer be treated by first-line antibiotics, other antibiotics must be used, which are both mo... more

Download (135)

View PDF (140)

Status Report - WHO Collaborating Centres in the Americas, 2022

Pan American Health Organisation PAHO (2022) C_WHO

Updated 2 June 2022.# This entry contains the Status Report of WHO Collaborating Centres in the Americas by Country and a new document with information of Collaborating Centres by Outcome of the Strategic Plan of the Pan American Health Organizatio... more

Herramienta de Evaluación del Control de Infecciones

USAID; Managment of Health Sciences MSH (2007) C1

Download (1127)

View PDF (986)

Guías para la atención de las principales emergencias obstétricas

Fescina R, De Mucio B, Ortíz El, Jarkin D. Ministerio de salud pública y bienestar social, Organización Panamericana de la Salud, et al. (2012) C1

Download (277)

View PDF (300)

HEARTS Paquete técnico para el manejo de las enfermedades cardiovasculares en la atencion primaria de salud. Evidencia: Protocolos de tratamiento clinico basados en la evidencia

Pan American Health Organization (PAHO) (2018) C_WHO

Los módulos que conforman el paquete técnico HEARTS están dirigidos a los formuladores de políticas públicas y gerentes, directores o coordinadores de programas a diferentes niveles dentro de los ministerios de salud cuyo trabajo influye sobre la prestación de servicios de salud a nivel prima... more

Download (335)

View PDF (251)

Guía de atención de la enfermedad de Chagas

Buendía, J. ; Agudelo Calderón,C. ; Pardo, R. ; et al Ministerio de la Protección Social, Colombia (2005) C1

La enfermedad de Chagas es el resultado de la infección por elTrypanosoma cruzi. En Colombia, zona endémica para la enfermedad, existe al menos un millón de personas infectadas y tres millones en riesgo. Por lo anterior, el Ministerio de la Protección Social avaló la creación de una Guía de a... more

Orientaciones para el manejo clínico de casos de síndrome de trombosis con trombocitopenia (‎STT)‎ tras la vacunación contra la COVID-19: orientaciones provisionales, 19 de julio de 2021

Organización Mundial de la Salud OMS (2021) C_WHO